Rare Neurological Disease Special Report

HNF Featured in Rare Neurological Disease Special Report

by | Apr 9, 2019 | 0 comments

rare neurological disease special report

The Hereditary Neuropathy Foundation is proud to announce that for the fifth year in a row, we have been featured in the annual Rare Neurological Disease Special Report—a widely-read supplement included in the mailing of the March issues of Neurology Reviews. It is also distributed at all major neurology conferences throughout the year, including the 2019 MDA Clinical and Scientific Conference in Orlando, Florida April 13th-17th. If you attend come visit HNF at the Neurology Reviews booth.

We are diligently educating neurologists and Health Care Providers about CMT on your behalf.

Neurology Reviews is the first and original news source in neurology and has a history of providing independent, unbiased news to neurologists and clinicians interested in the neurosciences.

Here is what HNF featured in the March, 2019 edition: 

  • HNF ad “What is CMT?” page 10

  • “FDA Hears the CMT Community Voice Loud and Clear on September 28, 2018” page 11

  • “CMT1A and Impaired Patient Mobility: Expressions, Remedies, and Impact of Quality of Life” page 12

  • HNF’s Industry Partners Pharnext & Acceleron page 35 & 36

  • HNF’s Research Partner Dr. Stephen Züchner page 38-41

  • PSA Genetic Testing Awareness for Neurologists page 80

As with all of HNF’s programs, we rely on donations and support from our industry sponsors, government grants and YOU! Please donate today to support our continued medical outreach initiatives.

Learn more on this topic

Related Blog Posts

Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency

United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to its lead drug candidate, PXT3003, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A) in patients 16 years and older.

Pharnext raises € 7.7 million in a private placement

Pharnext SA (FR0011191287 – ALPHA) (the “Company”), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, today announced a capital raise of circa € 7.7 million by way of issuance of 1,799,061 new ordinary shares (the “New Shares”) with one warrant attached each (together with the New Shares, the “ABSA”).

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news